EC Number   |
Specific Activity Minimum [µmol/min/mg] |
Specific Activity Maximum [µmol/min/mg] |
Reference |
|---|
   2.1.1.41 | -999 |
- |
- |
485326, 485327 |
| 2.1.1.41 | -999 |
- |
activity at various concentrations of glutathione |
485321 |
| 2.1.1.41 | -999 |
- |
cloning of SMT gene, sequence homologies and Western Blot comparable between Leishmania donovani, Leishmania infantum and Leishmania major, serological evaluation revealed that SMT is recognized by visceral leishmaniasis (VL) patients, immunized mice shown to have lower parasite burdens in both spleens and livers compared with non-immunized mice or mice injected with adjuvant alone |
690178 |
| 2.1.1.41 | -999 |
- |
comparison recombinant and wild-type |
485333 |
| 2.1.1.41 | -999 |
- |
prediction of secondary structure, eight residues at positions 79, 81, 82, 192, 217, 218, 219 and 223 critical for catalysis, scanning mutagenesis experiments involving a leucine replacement of 52 amino acids, substitution of key residues with functionally or structurally similar amino acids, 5 new residues at positions Y192, G217, G218, T219 and Y223 can switch the course of C1-transfer activity to include plant-like C2-transfer activity, model supported in which several conserved and non-conserved amino acids located in distinct regions regulate course of the C-methylation reaction toward product differences |
685376 |
| 2.1.1.41 | -999 |
- |
relative activity using 26,27-dehydrozymosterol as a substrate: wild-type 100%, mutant Y81F 300%, mutant Y81W 450%, mutant Y81I 25%, mutant Y81L 40%, mutant Y81V 15%, mutant Y81A 15% |
684723 |
| 2.1.1.41 | -999 |
- |
relative activity using zymosterol as a substrate: wild-type 100%, mutant Y81F 92%, mutant Y81W 124%, mutant Y81I 32%, mutant Y81L 37%, mutant Y81V 8%, mutant Y81A 8% |
684723 |
| 2.1.1.41 | 0.00000082 |
- |
bloodstream forms |
671372 |
| 2.1.1.41 | 0.00000217 |
- |
procyclic forms |
671372 |
| 2.1.1.41 | 0.0008 |
- |
purified enzyme |
485333 |
